Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Objective:
In this study the investigators aim at investigating:
Design:
The study is a prospective clinical intervention trial of 40 HIV-infected patients.
Method:
The investigator will administer the bacteria Lactobacillus Rhamnosus in capsular form to each patient 2 times a day in 8 weeks. At baseline and at the 8th week of the intervention, the investigators will collect blood samples, feces samples and make a positron emission tomography-magnetic resonance scans.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| HIV-infected patients | Experimental | Probiotics (lactobacillus rhamnosus) |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Probiotic | Drug | The probiotic strain Lactobacillus rhamnosus will be self-administrated twice a day, one capsule in the morning and one in the evening for eight weeks. |
|
| Measure | Description | Time Frame |
|---|---|---|
| change in Lipopolysaccharide (unit= endotoxin unit/mL) from baseline after intervention | will be measured in plasma samples | Will be measured before and after eight weeks of intervention. |
| Measure | Description | Time Frame |
|---|---|---|
| change in soluble cluster of differentiation 14 (unit (ng/mL) from baseline and eight weeks after intervention. | will be measured in plasma samples | Will be measured before and after eight weeks of intervention. |
| change in inflammation around the gut measured with positron emission tomography-magnetic resonance scans of the abdomen ( size of the lymph nodes and positron emission tomography-activity) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Susanne D Nielsen, MD, DMSc | Rigshospitalet, danmark | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rigshospitalet | Copenhagen | 2100 | Denmark |
The investigator plan to publish data in an article when the study is completed
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D019936 | Probiotics |
| ID | Term |
|---|---|
| D019587 | Dietary Supplements |
| D005502 | Food |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
positron emission tomography-magnetic resonance scans of the abdomen before an after intervention |
| Will be measured before and after eight weeks of intervention. |
| Changes in of high sensitive C-reactive protein (unit mg/l) from baseline and after eight weeks of intervention | will be measured in plasma samples | Will be measured before and after eight weeks of intervention. |
| Changes in measures of cytokines unit (pg/ml) at baseline and after eight weeks of intervention | will be measured in plasma samples | Will be measured before and after eight weeks of intervention. |
| Changes in the gut microbiota composition (454 pyrosequencing of fecal samples) from baseline to eight weeks after intervention (end of study) | stool-samples will be collected an analyzed by deep sequencing | Will be measured before and after eight weeks of intervention. |
| D019602 |
| Food and Beverages |